Compare SPCE & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | BNR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 252.7M |
| IPO Year | 2017 | 2019 |
| Metric | SPCE | BNR |
|---|---|---|
| Price | $2.50 | $16.01 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.86 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 13.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,036,000.00 | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | $2,528.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.47 | N/A |
| 52 Week Low | $2.18 | $2.18 |
| 52 Week High | $5.59 | $41.72 |
| Indicator | SPCE | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 29.59 |
| Support Level | $2.37 | $15.64 |
| Resistance Level | $2.67 | $24.23 |
| Average True Range (ATR) | 0.11 | 2.12 |
| MACD | 0.01 | -0.58 |
| Stochastic Oscillator | 17.31 | 9.65 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.